AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL VALENCIA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted data presented by researchers at the British Burn Association (BBA) Annual Meeting demonstrating reduced length of hospital stay among burn patients treated with RECELL®. The session, titled The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective, represents ...
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™ VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical publication evaluating Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, published in the Journal of Surgery (Akpunonu et al., 2025). According to the investigators, Cohealyx demonstrated significantly faster wound bed vascularization and autograft r...
AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the “Best New Technology Solution – Surgical” in the 2025 MedTech Breakthrough Awards. RECELL, FDA-approved for thermal burn wounds and full-thickness skin defects, has treated over 30,000 patients worldwide. RECELL r...
AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today See how innovation is transforming patient outcomes through real-world clinical insights and patient stories VALENCIA, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, is hosting its Acute Wound Care Showcase 2025 virtually today, May 13, 2025, at 11:00 a.m. Pacific Time. Attendees will hear directly from leading burn and trauma clinicians using AVITA Medical’s technologies, as well as from patients w...
AVITA Medical Reports First Quarter 2025 Financial Results VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, target...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025 VALENCIA, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will host its inaugural Acute Wound Care Showcase 2025 on Tuesday, May 13, 2025, via webcast at 11:00 a.m. Pacific Time. The event will feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs. The Acute Wound Care Showcase will provide an...
AVITA Medical to Announce First Quarter 2025 Financial Results VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent bus...
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025 Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical’s expanded portfolio, including RECELL, Cohealyx, and PermeaDerm VALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association (ABA) 2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona...
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure. In pre-clinical and initial ...
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it has entered into a new Contract Manufacturing Agreement for PermeaDerm® Biosynthetic Wound Matrix, along with an Amendment to its existing Exclusive Distribution Agreement with Stedical Scientific, Inc. These agreements further strengthen the strategic relationship between the two companies ...
AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference VALENCIA, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Jim Corbett, Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. Eastern Time. A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at . A replay of the webcast will be...
AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time). The webinar presentation will cover financial and ...
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recent Business Updates Commercial revenue of $18.4 million, an increase of approximately 30% compared to the same period in 2023Gross profit margin of 87.6%On December 19, 2024, the FDA granted 51...
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance VALENCIA, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its fourth quarter and full-year 2024 commercial revenue guidance. For the quarter ended December 31, 2024, AVITA Medical now expects commercial revenue to be approximately $18.4 million, reflecting growth of around 30% over the ...
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini. As a line extension of the RECELL GO system, the RECELL GO mini disposable cartridge is designed specifically to treat smaller woun...
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDermCohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for...
AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. A live audio webcast of the presentation will be accessible under the Events & Presentations section of ...
AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time. A live webcast of the fireside chat will be accessible under the Events & Presentations secti...
AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in commercial-stage regenerative medicine and pioneering devices for wound care management and skin restoration, today announced it has entered into an exclusive distribution agreement with Revolution Surgical Pty Ltd. This agreement marks an important milestone in our expansion into the Australian and New Zealand markets. Under the terms of the agreement, Revolution Surgica...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.